Navigation Links
Tengion Appoints A. Brian Davis Chief Financial Officer
Date:8/2/2010

EAST NORRITON, Pa., Aug. 2 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has appointed A. Brian Davis to the position of Chief Financial Officer.  Mr. Davis comes to Tengion after 15 years with Neose Technologies, Inc., a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, including cGMP production, development and research personnel at three sites. 

"Brian's demonstrated excellence as a public biotech company CFO, his strong accounting and finance background, and his experience supporting financial evaluation of business development transactions will be valuable to Tengion as we continue to advance the company and our product candidates," stated Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion.

Mr. Davis advanced from Controller to SVP and CFO at Neose, and brings highly relevant experience to Tengion including raising over $300 million in public and private equity and debt, financial evaluation of business development transactions, treasury and cash management, SEC reporting, Sarbanes-Oxley compliance, and investor relations.  Mr. Davis holds a BS in Accounting from Trenton State College and an MBA from the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.

Linda Hearne, Tengion's Vice President, Finance, will be stepping down from her role in order to relocate with her family overseas.  "During her nearly six years with Tengion, Linda has played a defining role in the development of our finance function and was instrumental in our becoming a public company earlier this year.  We wish Linda and her family all the best in their new life abroad and we are grateful that she will remain with Tengion in the coming weeks to ensure a smooth transition," said Dr. Nichtberger.  

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables us to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Our product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in the first half of 2010 for its lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder and is in pre-clinical development of its Neo-Kidney Augment™. Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
2. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
3. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
4. Tengion Announces Second Closing of Series C Financing
5. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
6. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
7. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
8. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
11. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... IA (PRWEB) , ... March 01, 2017 , ... ... announce finalization of an agreement that formalizes their clinical research partnership. Effective ... McFarland Clinic. This collaboration brings an increased opportunity for McFarland Clinic patients and ...
(Date:3/1/2017)... March 1, 2017  Elizabeth Young and Joshua ... the George Washington University,s Health Workforce Speaker series. ... Rosenthal will be speaking on March 9, 2017 ... Washington, DC at 12:00pm. ... invites nationally renowned speakers to examine new workforce configurations, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... Inc. (Newark, DE) have formed a strategic partnership to develop and market ... renewable energy laboratories. These automated testing solutions will save analysis time and ...
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
Breaking Biology News(10 mins):